FIELD: biotechnology.
SUBSTANCE: disclosed is a method of improving renal failure in an individual in need thereof, where the individual has multiple myeloma who has received at least two previous types of therapy for multiple myeloma. Methods involve administering an anti-CD38 antibody, pomalidomide and dexamethasone to an individual. Also disclosed is a kit for improving renal failure in an individual, where the individual has multiple myeloma, containing an anti-CD38 antibody, for use in combination with pomalidomide and dexamethasone.
EFFECT: invention can be used to improve renal failure in an individual suffering multiple myeloma.
41 cl, 8 dwg, 27 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS, THERAPY AND USE FOR TREATING MALIGNANT GROWTH | 2021 |
|
RU2831425C1 |
| FORMULATIONS BASED ON ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION | 2020 |
|
RU2838165C1 |
| DOSING REGIMES OF MELFLUFEN FOR CANCER DISEASES | 2016 |
|
RU2734930C2 |
| AGENT FOR TREATING MULTIPLE MYELOMA (MM) | 2016 |
|
RU2723047C2 |
| COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| METHOD OF TREATING PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY DOUBLE REFRACTORINESS WITH HELP OF NATURAL KILLER-CELL ADAPTIVE IMMUNOTHERAPY | 2024 |
|
RU2836995C1 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO CD38 AND LENALIDOMIDE | 2013 |
|
RU2698911C2 |
| SUBCUTANEOUS INJECTION OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2782950C2 |
